Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes

Sponsor
Dr. Zarmina Younes
Study ID
NCT07541456
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin — DRUG
    Empagliflozin 10 mg once daily for the first 4 weeks, increased to 25 mg once daily until week 12.
  • Metformin — DRUG
    Metformin 500 mg twice daily for 12 weeks.

Study Details

This randomized controlled trial studied whether empagliflozin lowers blood pressure better than non-SGLT2 oral hypoglycemic treatment in adults with type 2 diabetes mellitus and hypertension. A total of 300 participants were assigned to 1 of 2 treatment groups and followed for 12 weeks. One group received empagliflozin and the other received non-SGLT2 oral therapy. Blood pressure was measured at baseline and again after 12 weeks to compare the effect of treatment on systolic and diastolic blood pressure.

Key Dates

Start date
Jun 9, 2025
Status verified
Apr 2026
Primary completion
Nov 8, 2025
Completion
Nov 8, 2025

Study Design

Enrollment
300 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin
    Participants received empagliflozin 10 mg once daily for the first 4 weeks, increased to 25 mg once daily until week 12.
  • Active Comparator: Metformin
    Participants received metformin 500 mg twice daily for 12 weeks.

Primary Outcome Measure

Change in Systolic Blood Pressure [ Time Frame: Baseline to 12 weeks ]

Related Studies